Belantamab mafodotin: all 53 studies that test it

Page 1 of 1. Open to participants first (17), then studies with results posted, then the rest; newest registration first within each.

• Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.Not yet recruitingNCT07748689Phase 2
• TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)Not yet recruitingNCT07720843Phase 1
• Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07614360Phase 2
• A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic ImpairmentNot yet recruitingNCT07609706Phase 1
• Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple MyelomaRecruitingNCT07285239Phase 3
• A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) AmyloidosisRecruitingNCT07224672Phase 2
• A PHASE II TRIAL AIMING TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA PREVIOUSLY TREATED WITH A THROMBOPOIETIN RECEPTOR AGONIST AND/OR RITUXIMAB AFTER CORTICOSTEROID FIRST-LINE THERAPYNot yet recruitingNCT07019545Phase 2
• A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)RecruitingNCT06679101Phase 3
• Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple MyelomaRecruitingNCT05922501Phase 2
• Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple MyelomaRecruitingNCT05853965Phase 1/2
• Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple MyelomaRecruitingNCT05847569Phase 2
• Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple MyelomaRecruitingNCT05789303Phase 2
• A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination TreatmentsRecruitingNCT05714839Phase 1/2
• Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk MyelomaRecruitingNCT05208307Phase 2
• Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL AmyloidosisRecruitingNCT05145816Phase 1/2
• Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT05091372Phase 2
• A Phase 1 With Extension Cohort, Single Arm, Single Center, Open Label Trial of Belantamab Mafodotin for the Treatment of High-Risk Smoldering Multiple MyelomaRecruitingNCT05055063Phase 1
• Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMMActive, not recruitingNCT07217184Phase 1/2Results posted
• Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMMActive, not recruitingNCT07217119Phase 1/2Results posted
• Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMMActive, not recruitingNCT07150104Phase 1/2Results posted
• Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMMActive, not recruitingNCT07150091Phase 1/2Results posted
• Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMMActive, not recruitingNCT07084896Phase 1/2Results posted
• All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT06956170Phase 3Results posted
• Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT06868667Phase 3Results posted
• China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT06868654Phase 3Results posted
• Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMMTerminatedNCT06655818Phase 1/2Results posted
• Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMMTerminatedNCT06160609Phase 1/2Results posted
• Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple MyelomaTerminatedNCT05117008Phase 2Results posted
• Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT05064358Phase 2Results posted
• Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple MyelomaTerminatedNCT04896658Phase 1/2Results posted
• Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell LymphomaTerminatedNCT04676360Phase 2Results posted
• Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab MafodotinTerminatedNCT04549363Phase 3Results posted
• Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT04484623Phase 3Results posted
• A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal FunctionActive, not recruitingNCT04398745Phase 1Results posted
• Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT04246047Phase 3Results posted
• A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)CompletedNCT04177823Phase 1Results posted
• Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)Active, not recruitingNCT04162210Phase 3Results posted
• Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of GSK2857916CompletedNCT02064387Phase 1Results posted
• A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory MyelomaWithdrawnNCT05874193Phase 2
• A Study of Belantamab Mafodotin in Combination With Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or Has Come Back After TreatmentActive, not recruitingNCT05556798Phase 1
• Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation in Patients With Relapse Refractory Multiple MyelomaTerminatedNCT05065047Phase 1
• Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractory to LenalidomideActive, not recruitingNCT05060627Phase 1/2
• Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple MyelomaActive, not recruitingNCT05002816Phase 1/2
• Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell TransplantActive, not recruitingNCT04876248Phase 2
• Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple MyelomaActive, not recruitingNCT04822337Phase 1/2
• Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT04808037Phase 1/2
• Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma PatientsActive, not recruitingNCT04802356Phase 2
• Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple MyelomaActive, not recruitingNCT04680468Phase 2
• A Study of Belantamab Mafodotin in Patients With Relapsed or Refractory AL AmyloidosisCompletedNCT04617925Phase 2
• A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic FunctionWithdrawnNCT04398680Phase 1
• Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple MyelomaActive, not recruitingNCT04091126Phase 1
• Myeloma-Developing Regimens Using Genomics (MyDRUG)CompletedNCT03732703Phase 1/2
• Multi-Center Study of GSK2857916 in Combination With Pomalidomide and DexActive, not recruitingNCT03715478Phase 1/2

← Belantamab mafodotin overview